Address: 50 Soldiers Field Place, Boston, MA 02135 (America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Cell line-derived xenograft (CDX) models are among the most commonly used research models for efficacy evaluation of anti-cancer therapies. CDX models are created by implanting cancer cell lines into immunodeficient mice and have contributedsignificantly to the development of cancer drug therapies. The establishment of CDX models involves inoculation of tumor cells (including various types of cancer cells) into immunodeficient mice.
After high-throughput drug screening in vitro, the CDX model is then used for in vivo drug infusion and efficacy evaluations. Due to long-term cell passage in vitro, cells have the characteristics of high homology and reproducibility. However, cell lines often lose their original biological characteristics through many passages. CDXs can be complementary to tumor biopsies and PDXs. CDXs offer an opportunity to generate models for those patients that cannot undergo surgery or an alternative invasive procedure.
Cancer Type | Cell Lines |
Brain cancer | U-87 MG, LN-229, SH-SY5Y |
Breast cancer | BT474, HCC1569, HCC1954, HCC70, JIMT-1, MCF7, MDA-MB-231, MDA-MB-468, MX-1, SUM149PT, ZR-75-1 |
Colon cancer | COLO 205, DLD-1, HCT-116, HCT-15, HT-29, LIM-1215, LoVo, Ls174T, NCI-H580, RKO, SW480, SW620 |
Endometrium | AN3 CA, HEC-1-A |
Fibrosarcoma | HT-1080 |
Gastric cancer | Hs 746T, MKN-45, NCI-N87, SNU-16 |
Head and neck cancer | TT, FaDu |
Leukemia | CCRF-CEM, HEL, HL-60, K-562, MV-4-11, THP-1 |
Liver cancer | Hep G2, HuH-7 |
Lung cancer | A549, Calu-1, Calu-3, Calu-6, HCC827, MOTO-211H, NCI-H1299, NCI-H1650, NCI-H1975, NCI-H2122, NCI-H358, NCI-H460, NCI-H520, NCI-H2228, NCI-H526, NCI-H69, NCI-H727, PC9, A427 |
Lymphoma | SU-DHL-4, DB, SU-DHL-6, Mino, Daudi, JeKo-1, Raji, TMD-8, WSU DLCL2, DOHH2, OCI-LY19, OCI-HL10, MOLM13, U-937 |
Melanoma | A375 |
Myeloma | MM.1S, NCI-H929, RPMI-8226 |
Osteosarcoma | SJSA-1 |
Ovarian cancer | A2780, OVCAR-3, SK-OV-3 |
Pancreatic cancer | AsPC-1, Bx PC-3, Capan-1, Capan-2, CFPAC-1, HPAF-II, Mia PaCa-2, PANC-1, SU.86.86 |
Prostate cancer | DU145, PC-3 |
Renal cancer | 786-O, OS-RC-2, A498 |
Skin cancer | A-431 |